T 1700/19 (Tenofovir alafenamide hemifumarate / GILEAD) of 14.03.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T170019.20230314
- Date of decision
- 14 March 2023
- Case number
- T 1700/19
- Petition for review of
- -
- Application number
- 12753867.6
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- TENOFOVIR ALAFENAMIDE HEMIFUMARATE
- Applicant name
- Gilead Sciences, Inc.
- Opponent name
- Teva Pharmaceutical Industries Ltd
Sandoz GmbH
FRKelly - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54(2)European Patent Convention Art 54(3)European Patent Convention Art 56European Patent Convention Art 83European Patent Convention R 103(1)(a)European Patent Convention R 111(2)
- Keywords
- Novelty - main request (yes)
Sufficiency of disclosure - main request (yes)
Inventive step - main request (yes)
Substantial procedural violation - (no) - Catchword
- -
- Cited cases
- G 0001/15
- Citing cases
- -
Order
For these reasons it is decided that:
1. The appeals are dismissed.
2. The request for reimbursement of the appeal fee is rejected.